Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00795210 · ClinicalTrials.gov registry record · NA
Effects of Short-term Growth Hormone in HIV-infected Patients
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT00795210: Completed NA study, sponsored by Massachusetts General Hospital.
NCT00795210 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00795210, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the short-term effects of two different doses of growth hormone, compared to treatment with growth hormone releasing hormone, on the brain's secretion of growth hormone and the body's glucose metabolism. We hypothesize that growth hormone administration will alter the body's endogenous pulsatile growth hormone secretion and that higher dose growth hormone may decrease insulin sensitivity. We hypothesize that growth hormone releasing hormone will augment endogenous GH pulsatility and be neutral to insulin sensitivity.
Interventions
- DRUG Growth hormone
- DRUG Growth Hormone Releasing Hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00795210
The ClinicalTrials.gov registry entry for NCT00795210 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Growth hormone is the first listed.
NCT00795210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00795210 about?
NCT00795210 is a clinical study titled "Effects of Short-term Growth Hormone in HIV-infected Patients". The purpose of this study is to examine the short-term effects of two different doses of growth hormone, compared to treatment with growth hormone releasing hormone, on the brain's secretion of growth hormone and the body's glucose metabolism. We hypothesize that growth hormone administration will a...
What is the current status of trial NCT00795210?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2009-02. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00795210?
The interventions under investigation include: Growth hormone (DRUG), Growth Hormone Releasing Hormone (DRUG).
Who is sponsoring clinical trial NCT00795210?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.